"CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland-(BUSINESS WIRE)-Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific partnership. The collaboration brings together eProtein Discovery's ™ rapid multiplex membrane protein screening with leadXpro's AI/ML-driven construct design and membrane protein expertise to advance structural studies and therapeutic development."
"Integrating eProtein Discovery's Cell Free Protein Synthesis multiplex screening technology with leadXpro's AI/ML and biophysical and structural characterization expertise, the partnership will establish an AI-guided, iterative, end-to-end workflow. The workflow will link in silico construct design with rapid, experimental multiplex screening to accelerate and de-risk challenging membrane protein programs, shortening the path to structural and biophysical insights for structure-based drug discovery."
Nuclera and leadXpro will combine rapid multiplex cell-free membrane protein screening with AI/ML-driven construct design and membrane protein expertise to accelerate structural studies and therapeutic development. Membrane proteins, which are high-value but difficult drug targets, often fail to yield sufficient quantity and quality for structural biology and biophysical characterization. The integrated workflow will link in silico construct design to rapid experimental multiplex screening, enabling iterative optimization. Promising constructs will undergo biophysical characterization and high-resolution cryo-EM, and resulting insights will feed AI/ML models to improve construct stability, yields and functionality, shortening timelines for structure-based drug discovery.
Read at Silicon Canals
Unable to calculate read time
Collection
[
|
...
]